Significance of β-Galactoside α2,6 Sialyltranferase 1 in Cancers
AbstractAltered glycosylation is a common feature of cancer cells. It takes a variety of forms, which includes loss of expression or excessive expression of some structures, the accumulation of precursors, the appearance of novel structures, etc. Notably, these changes in glycan structure do not occur as a random consequence of disorder biology. Only a limited subset of oligosaccharides is found frequently enriched on the tumor cell surface and implicated in different tumor phenotypes. Among these, altered sialylation has long been associated with metastatic cell behaviors such as invasion and enhanced cell survival and accumulating evidence points to the alteration occurring in the sialic acid linkage to other sugars, which normally exists in three main configurations: α2,3, α2,6, and α2,8, catalyzed by a group of sialyltransferases. The aberrant expression of all three configurations has been described in cancer progression. However, the increased α2,6 sialylation catalyzed by β-galactoside α2,6 sialyltranferase 1 (ST6Gal I) is frequently observed in many types of the cancers. In this review, we describe the findings on the role of ST6Gal I in cancer progression, and highlight in particular the knowledge of how ST6Gal I-mediated α2,6 sialylated glycans or sialylated carrier proteins regulate cell signaling to promote the malignant phenotype of human carcinoma. View Full-Text
Share & Cite This Article
Lu, J.; Gu, J. Significance of β-Galactoside α2,6 Sialyltranferase 1 in Cancers. Molecules 2015, 20, 7509-7527.
Lu J, Gu J. Significance of β-Galactoside α2,6 Sialyltranferase 1 in Cancers. Molecules. 2015; 20(5):7509-7527.Chicago/Turabian Style
Lu, Jishun; Gu, Jianguo. 2015. "Significance of β-Galactoside α2,6 Sialyltranferase 1 in Cancers." Molecules 20, no. 5: 7509-7527.